Hutchmed, Innovent jointly announce NDA acceptance in China
HUTCHMED (HCM) and Innovent Biologics 'jointly announce that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor has been accepted for review by the China National Medical Products Administration. The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced renal cell carcinoma. The study has met its primary endpoint of progression free survival, as assessed by blinded independent central review according to RECIST 1.1 criteria. The combination also demonstrated improvements in secondary endpoints including objective response rate and duration of response. The safety profile was tolerable and no new safety signals were observed. Data from FRUSICA-2 will be submitted for presentation at an upcoming scientific conference.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
New coronavirus discovered in China ‘only small step' from infecting humans
A new coronavirus discovered in China is only a small step from mutating and causing another global pandemic, experts have warned. Scientists believe the variant, called HKU5-CoV-2, may infect a broader range of animals than Covid-19 – which caused millions of deaths – and may have more potential for jumping between species. US researchers fear that HKU5-CoV-2, found in China, in February, could also infect humans, leading to a widespread outbreak. The new study, published in Nature Communications, looked at a lesser-known group of coronaviruses called merbecoviruses, which includes HKU5 and MERS-CoV, which is responsible for the deadly Middle East Respiratory Syndrome. The team from Washington State University looked at how the new pathogen interacts with human cells. They found that a small change in the virus's spike protein could allow it to attach to human ACE2 cells in people's throats, mouths and noses. HKU5-CoV-2 can infect and replicate inside human cells in both the airways and gut. According to the World Health Organisation, about 35 per cent of people infected with Middle East Respiratory Syndrome die. Since 2012, some 27 countries have reported cases, leading to 858 known deaths due to the infection, which spread from camels. But when HKU5 was discovered in February, scientists warned against exaggerating the risks because it does not enter human cells as readily as Sars-CoV-2, which caused Covid-19. HKU5 was first detected in bats by scientists from the Chinese laboratory where some say Covid originated in 2019. Prof Michael Letko, a virologist who co-led the study, said: 'HKU5 viruses in particular really hadn't been looked at much, but our study shows how these viruses infect cells. 'What we also found is HKU5 viruses may be only a small step away from being able to spill over into humans.' When Covid-19 emerged it was widely blamed on markets in China where different breeds of wild animal are kept caged and often slaughtered close to other animals. Meat is sold at the open-air stalls. Critics said the markets were the perfect breeding ground for new zoonotic diseases – those that spread to humans – to emerge. The scientists, whose experiments studied how the new pathogen interacts with human cells, believe the virus would have to carry certain mutations if it were to infect humans. 'These viruses are closely related to MERS, so we have to be concerned if they ever infect humans,' Prof Letko said. 'While there's no evidence they've crossed into people yet, the potential is there and that makes them worth watching.'
Miami Herald
10 hours ago
- Miami Herald
Axiom Space's record-setter to lead astronauts from 3 nations on private mission
Peggy Whitson has spent nearly two years of her life in space as an Axiom Space employee and former NASA astronaut. Next week she'll lead a mission with three men representing countries that haven't sent anyone to space in more than four decades. Whitson, 65, will command the Ax-4 mission targeting liftoff as early as 8:22 a.m. Tuesday from Kennedy Space Center's Launch Pad 39-A. It will transport three Axiom customers: one each from India and Hungary, whose seats were paid for by their governments, and one from Poland through the European Space Agency. Whitson flew three times for NASA before joining Axiom, for which she commanded the Ax-2 mission in 2023 and tallied more than 675 days in space. She holds the record for most time in space by a woman and most for any American. All four of her missions were to the International Space Station - as is the Ax-4 flight. "For me, returning to space is always a special experience. Every mission is different," she said during a call with media Tuesday. "Every crew brings something new to the table. I've been incredibly impressed by the dedication and the work ethic and the passion of this team. "It's been a joy to train alongside them and I'm looking forward to seeing them in microgravity." That crew members are Shubhanshu Shukla of India, acting as mission pilot; mission specialist Sławosz Uznański of Poland, an ESA project astronaut; and mission specialist Tibor Kapu of Hungary. The quartet will climb aboard a new SpaceX Crew Dragon - which will get its official name once it reaches orbit - launching atop a Falcon 9 rocket on only the second human spaceflight of the year from Space Coast following the March launch of Crew-10. The Dragon is slated to dock with the space station Wednesday at 12:30 p.m. for a planned two-week stay during which crew members will participate in a heavy schedule of science experiments, technology demonstrations and media outreach. "We'll be conducting research that spans biology, material and physical sciences as well as technology demonstrations," Whitson said. "We'll also be engaging with students around the world, sharing our experience and inspiring the next generation of explorers." One science experiment she's most interested in could pave the way for people who are diabetic to travel into space. "A person with diabetes can't fly in space because it's disqualifying and not considered to be safe, because we wouldn't know how their bodies would respond," Whitson said. "So if we have the appropriate technology to monitor the individuals, we feel that we can open up that door and that path for a lot of folks in the world and just open up space a little bit more." Delving into a customer base of countries which don't have as much access to space is part of Axiom's business plan. For this mission, the three countries represented first flew to space with the Soviet Union as cosmonauts on Soyuz spacecraft, but nothing since 1984, although a Hungarian-American millionaire flew to the space station twice as a tourist in 2007 and 2009. The governments paid Axiom an undisclosed amount for their representatives' trip to the space station. It marks the third time it has flown government-sponsored passengers after its first trip to the station in 2022 had three men who paid $55 million each for their visit. Whitson's last trip on Ax-2 had just one private passenger who paid their own way. The Saudi Arabian government paid for the other two passengers. Since then, Axiom has focused on only government-sponsored customers. Ax-3 in 2024 had passengers from Italy, Turkey and Sweden. Similar to Uznański on this mission, the ESA paid for the Swedish customer even though the agency has access to the space station as a partner with NASA, Canada, Japan and Russia. The trio of space newcomers on this mission all spoke of it as opening up possibilities for their nations. "I carry with me, not just instruments and equipment, but the hopes and dreams of a billion hearts," said India's Shukla, who will perform seven experiments for research institutions from his nation. "These experiments will pave the way for India's progress in microgravity science, and I'm proud to be the bridge between Earth and orbit for this pioneering research, balancing the scientific ambition with a rich cultural heritage." Poland's Uznański noted that he will enjoy the view. "I'm looking forward to floating in the cupola, which is our window back on Earth. I can't wait to see all the training places, and also our four countries from up there, but mostly to see Earth as a whole, as one planet, one home," he said. Kapu will do 25 experiments for Hungary while also using half of his personal luggage space to bring something that pays homage to the first Hungarian who flew to space in 1978. "There was a teddy bear which is wearing a cosmonaut space suit. This teddy bear is from a Hungarian TV show for kids," he said, noting it went along for the ride nearly 50 years ago. "I'm really proud to fly that again." It won't be the only stuffed animal on the flight. The other is a swan called Joy, named by Kapu, that will function as the crew's "zero-gravity indicator" - traditionally an object that lets astronauts know they've reached space as it begins to float around after launch. Whitson teased the swan's connection to the name reveal for the Crew Dragon capsule. The first four Crew Dragons were named Endeavour, Resilience, Endurance and Freedom. "The reason we selected this one might become more obvious once you hear the name of the vehicle," she said. "You'll have to wait for that one." -------------- Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
